A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Trial Profile

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2018 Planned primary completion date changed from 30 Jun 2019 to 1 Jan 2019.
    • 10 Jan 2018 Planned End Date changed from 1 Jan 2019 to 30 Jun 2019.
    • 10 Jan 2018 Planned primary completion date changed from 1 Jan 2019 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top